Back to top
more

Amedisys (AMED)

(Delayed Data from NSDQ)

$100.99 USD

100.99
1,060,060

0.00 (0.00%)

Updated Aug 14, 2025 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 12% (29 out of 246)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?

by Zacks Equity Research

Sector ETF report for PTH

Zacks Equity Research

Here's Why You Should Buy IDEXX Laboratories (IDXX) Stock

by Zacks Equity Research

IDEXX (IDXX) continues to demonstrate solid growth globally, with strong international expansion.

Zacks Equity Research

Amedisys (AMED) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Amedisys (AMED) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Chandrima Sanyal headshot

3 Investment Tips to Help You Achieve Your 2019 Goals

by Chandrima Sanyal

Here are a few ways to invest your money that will help you improve your financial health and mitigate the impacts of any potential adversity.

Zacks Equity Research

Amedisys (AMED) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Amedisys (AMED) closed the most recent trading day at $129.41, moving +1.47% from the previous trading session.

Zacks Equity Research

Illumina (ILMN) Q4 Earnings Lag Estimates, Revenues Top Mark

by Zacks Equity Research

Illumina's (ILMN) Q4 figures show a sturdy uptick in sequencing consumable revenues.

Zacks Equity Research

ADUS vs. AMED: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

ADUS vs. AMED: Which Stock Is the Better Value Option?

Zacks Equity Research

Is Amedisys (AMED) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (AMED) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?

by Zacks Equity Research

Sector ETF report for PSCH

Zacks Equity Research

Here's Why You Should Snap Up Abbott (ABT) Stock Right Now

by Zacks Equity Research

We are optimistic about the strong and consistent performance of Abbott's (ABT) EPD segment. The company's Diabetes Care business has been hogging the limelight on strength in FreeStyle Libre.

Zacks Equity Research

Thermo Fisher (TMO) Down on Business Divestment Declaration

by Zacks Equity Research

Thermo Fisher's (TMO) Anatomical Pathology business comes under its Specialty Diagnostics segment catering to customers at healthcare and clinical laboratories.

Zacks Equity Research

Here's Why You Should Buy Tandem Diabetes (TNDM) Stock Now

by Zacks Equity Research

Strength in domestic sales along with the recent launch of the t:slim X2 Insulin Pump in selected international markets bode well for Tandem Diabetes (TNDM).

Zacks Equity Research

Zacks.com featured expert Kevin Matras highlights: Caseys General Stores, Shoe Carnival, Amedisys, Expeditors International of Washington and Stitch Fix

by Zacks Equity Research

Zacks.com featured expert Kevin Matras highlights: Caseys General Stores, Shoe Carnival, Amedisys, Expeditors International of Washington and Stitch Fix

Zacks Equity Research

Henry Schein Animal Health Spin-Off Approaches, Costs Mount (revised)

by Zacks Equity Research

Henry Schein's (HSIC) animal health spin-off will help it boost growth opportunities in dental space to deliver quality clinical care plus advanced wellness and prevention.

Sanghamitra Saha headshot

Bet on DuPont Analysis: Play 5 Quality Stocks

by Sanghamitra Saha

Bet on five top-ranked stocks with higher ROE derived the DuPont way.

Zacks Equity Research

Quest Diagnostics' Core Diagnostics Strong Amid Several Woes

by Zacks Equity Research

Quest Diagnostics' (DGX) steady efforts to intensify focus on core diagnostic information services business and an intelligent capital management give investors ample reasons to cheer for.

Zacks Equity Research

Amedisys (AMED) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Amedisys (AMED) closed at $127 in the latest trading session, marking a +0.09% move from the prior day.

Zacks Equity Research

Can Medical Devices Strength Drive Abbott (ABT) Q4 Earnings?

by Zacks Equity Research

Abbott (ABT) Q4 results likely to show continued growth in Medical Devices business.

Zacks Equity Research

Here's Why You Should Buy Myriad Genetics (MYGN) Stock Now

by Zacks Equity Research

On the success of the Elevate 2020 program, along with augmenting reimbursements for tests, Myriad Genetics (MYGN) seems to be well-positioned to deliver strong financial results in fiscal 2019.

Zacks Equity Research

Henry Schein Animal Health Spin-Off Approaches, Cost Mounts

by Zacks Equity Research

Henry Schein's (HSIC) animal health spin-off will help it boost growth opportunities in dental space to deliver quality clinical care plus advanced wellness and prevention.

Zacks Equity Research

Why You Should Consider Buying Omnicell (OMCL) Stock Now

by Zacks Equity Research

Omnicell (OMCL) is pulling out all the stops to strengthen the medication adherence segment.

Zacks Equity Research

QIAGEN QFT-Plus Ok'd in Canada, Test Customer Base Expands

by Zacks Equity Research

QIAGEN (QGEN) progresses with plans to widen customer base for QuantiFERON-TB Gold Plus test.

Zacks Equity Research

Is Amedisys (AMED) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Is (AMED) Outperforming Other Medical Stocks This Year?

Zacks Equity Research

Here's Why You Should Invest in Illumina (ILMN) Stock Now

by Zacks Equity Research

Illumina's (ILMN) product launches continue to contribute to the top line. The company's recent broadening of genotyping sequencing line buoys optimism.

Tirthankar Chakraborty headshot

New Strong Buy Stocks for January 10th

by Tirthankar Chakraborty

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday